[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592278":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":34,"locations":44,"responsibleParty":80,"collaborators":34,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":34,"enrollmentInfo":92,"targetDuration":34,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Carnot Laboratories","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-erosive GERD - Test product","EXPERIMENTAL","Non-erosive GERD - Tegoprazan",[13],"Drug: Tegoprazan",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-erosive GERD - Comparator","ACTIVE_COMPARATOR","Non-erosive GERD - Pantoprazole",[19],"Drug: Pantoprazole",{"label":21,"type":10,"description":22,"interventionNames":23},"Erosive GERD - Test product","Erosive GERD - Tegoprazan",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Erosive GERD - Comparator","Erosive GERD - Pantoprazol",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Tegoprazan","Tegoprazan 50 mg daily for 28 days",[21,9],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Pantoprazole","Pantoprazole 40 mg daily for 28 days",[25,15],[40],{"name":41,"affiliation":42,"role":43},"Jose M Remes-Troche, Dr","Digestive Physiology and Motility Lab, Instituto de Investigaciones Médico Biológicas, Veracruz , México","PRINCIPAL_INVESTIGATOR",[45,65],{"facility":46,"status":47,"city":48,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Gastrologen S.A. de C.V.","RECRUITING","Mexico City","01900","Mexico","MX",{"type":53,"coordinates":54},"Point",[55,56],-99.12766,19.42847,{"lat":56,"lon":55},[59,64],{"name":60,"role":61,"phone":62,"phoneExt":34,"email":63},"Luis R Valdovinos-Garcia, Dr","CONTACT","+52 (55) 6464 4227","drprapul@gmail.com",{"name":60,"role":43,"phone":34,"phoneExt":34,"email":34},{"facility":66,"status":47,"city":67,"state":68,"zip":69,"country":50,"countryCode":51,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Saluz Investigación, S.C.","Boca del Río","Veracruz","94299",{"type":53,"coordinates":71},[72,73],-94.71028,17.71333,{"lat":73,"lon":72},[76,79],{"name":41,"role":61,"phone":77,"phoneExt":34,"email":78},"+52 (229) 921 8869","jose.remes.troche@gmail.com",{"name":41,"role":43,"phone":34,"phoneExt":34,"email":34},{"type":81,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100592278","phase-4-clinical-trial-for-the-comparative-evaluation-of-acid-suppression-and-symptom-management-of-gastroesophageal-reflux-disease-with-the-administration-of-tegoprazan-or-pantoprazole-100592278",false,"NCT06991348","Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole","Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERD","TOP-GERD","Inclusion Criteria:\n\n* With endoscopic diagnosis of GERD or NERD (endoscopy ≤ 15 days old)\n* With positive impedance pHmetry results (pHmetry ≤ 15 days old)\n* With recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old\n\nExclusion Criteria:\n\n* With known hypersensitivity to tegoprazan, pantoprazole, or any of the components of each formulation\n* Subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine\n* Nephropathic and\u002For hepatopathic subjects (including non-alcoholic hepatitis)\n* Subjects with upper gastrointestinal tract bleeding\n* Subjects with gastric and\u002For duodenal ulcer 2 months prior to screening\n* Subjects with a history of esophageal or gastric surgery","ALL","18 Years",{"count":93,"type":94},128,"ESTIMATED","INTERVENTIONAL",[97],"PHASE4","The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.",[100],"Gastroesophageal Reflux Disease",[102,103,104,105,106],"GERD","pantoprazole","tegoprazan","P-CAB","PPI","2025-07-18",{"date":109,"type":110},"2025-07-23","ACTUAL",{"date":112,"type":110},"2024-07-30",{"date":114,"type":94},"2025-11-30",{"name":5,"class":6},2]